(Q37201524)

18 August 2017

1 reference

title

HER2-positive breast cancer: current treatment strategies (English)

1 reference

18 August 2017

1 reference

Edith A Perez

1

1 reference

18 August 2017

Mansoina Baweja

series ordinal

2

1 reference

18 August 2017

publication date

1 July 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

26

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

545-552

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900801971024

10.1080/07357900801971024

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference